Zhengzhou, Aug 28, 2026 — Henan Provincial Medical Security Bureau opened public consultations on adjusting medical insurance payment standards for select medical consumables, including coronary intervention balloon catheters and cardiac pacemakers, following provincial alliance procurement executions, while moving leadless pacemakers out of the negotiated consumables catalog into general management.
Policy Snapshot
| Attribute | Detail |
|---|---|
| Issuer | Henan Provincial Medical Security Bureau |
| Document | Notice on Soliciting Opinions on Adjusting Payment Standards for Some Medical Consumables Under Medical Insurance |
| Scope | Coronary intervention balloon catheters; cardiac pacemakers; related inter-provincial alliance procurement batches |
| Key change | Leadless implantable cardiac pacemaker removed from negotiated consumables catalog, reclassified as general consumable |
| Legal basis | Henan Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Medical Consumables Catalog (2025) (Yu Yi Bao Ban [2025] No. 85) |
| Affected notices | Yu Yi Bao Ban [2026] No. 35 (10 batches); Yu Yi Bao Ban [2026] No. 47 (2 batches) |
| Comment deadline | Sept 12, 2026, 17:00 CST |
| Contact | Wang Minghua, 0371-69698064, hnybjyyc@126.com |
Key Adjustments
The bureau proposed payment standard revisions for medical consumables covered under two provincial alliance procurement execution notices—one spanning 10 batches of coronary intervention balloons and related items, the other covering two batches of cardiac pacemakers. The most significant structural change involves the reclassification of the leadless implantable cardiac pacemaker from the negotiated consumables directory to general consumable management, effectively removing it from the separate negotiation track and subjecting it to standard reimbursement protocols.
Market Impact Analysis
The payment standard adjustments reflect the downstream policy synchronization that follows large-scale inter-provincial volume-based procurement for high-value cardiac devices. For manufacturers, the recalibration of reimbursement benchmarks will directly affect net pricing after insurance settlement, potentially compressing margins for coronary balloons and traditional pacemakers that were already subject to steep procurement-driven price cuts.
The reclassification of leadless pacemakers from negotiated to general consumable status is particularly consequential. Leadless pacemakers—premium devices that command significantly higher prices than conventional transvenous systems—had previously been shielded under the negotiated catalog, which typically allows for separate price agreements and more favorable reimbursement rates. Moving them to general consumable management signals a potential reimbursement downgrade, forcing manufacturers to absorb lower insurance payment ceilings or risk reduced hospital adoption as out-of-pocket costs rise for patients.
For hospitals and distributors, the adjustment clarifies the post-procurement reimbursement landscape, reducing administrative ambiguity but potentially tightening payment flows for high-end cardiac implants. The 15-day comment window suggests regulators intend to finalize standards by late September, leaving limited time for industry stakeholders to shape payment benchmarks.
Forward-Looking Statement
Industry analysts expect Henan’s template to be replicated across additional provinces that participated in the same inter-provincial procurement alliances, triggering a wave of payment standard harmonization for cardiac consumables in the fourth quarter of 2026. The leadless pacemaker reclassification may foreshadow a broader regulatory push to rationalize reimbursement tiers for premium implantable devices, potentially extending to structural heart and neurostimulation products. Companies with significant exposure to Henan’s cardiac device market should prepare for compressed reimbursement margins and evaluate pricing strategies that balance procurement compliance with sustainable hospital economics. Final rules are anticipated by late September or early October 2026.-China Health Reform Pulse
Policy Source: http://ylbz.henan.gov.cn/2026/08-28/3408750.html